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Chemoprevention may be one way to prevent lung cancer in smokers who are motivated to quit
but cannot stop. The approach to chemoprevention of lung cancer described in this article is
based on an understanding of the lung carcinogens present in tobacco smoke. The available data
indicate that the compounds in cigarette smoke most likely involved in the induction of lung
cancer in humans are the complex of polynuclear aromatic hydrocarbons typified by
benzo[a]pyrene (B[a]P) and the tobacco-specific nitrosamine 4-(methyinitrosamino)-143-pyridyl-1-
butanone (NNK). A large number of compounds are now available that inhibit lung tumorigenesis
by Bla]P or NNK in rodents. Inhibition of NNK-induced lung carcinogenesis by phenethyl
isothiocyanate (PEITC) and inhibition of Bla]P-induced lung carcinogenesis by benzyl
isothiocyanate (BITC) are discussed as examples. Studies with PEITC in rodents clearly
demonstrate that it inhibits NNK-induced lung tumorigenesis by inhibiting the metabolic activation
of NNK. Similar changes appear to occur in humans according to data generated in smokers who
ate watercress, a source of PEITC. It is likely that mixtures of chemopreventive agents with activity
against carcinogens in tobacco smoke, such as NNK and B[aJP, will be useful in chemoprevention
of lung cancer in smokers. Furthermore, there is a need to develop suppressing agents for lung
cancer that might be applicable in both smokers and ex-smokers. - Environ Health Perspect
105(Suppl 4):955-963 (1997)
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Introduction
Lung cancer is the leading cause ofcancer
death in the United States, with over
160,000 deaths expected in 1997 (1).
Smoking causes at least 80% oflung cancer
(2). Therefore, smoking cessation is dearly
the best way to decrease incidence and
mortality from the great majority oflung
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cancer; however, smoking cessation has not
been uniformly successful. Available data
indicate that approximately 26% of the
adult population in the United States still
smokes, in spite ofwidespread knowledge
of the associated hazards (3). Many of
these people are addicted to nicotine and
cannot stop smoking even after partici-
pation in smoking cessation programs and
use of the nicotine patch. Chemo-
prevention may be a way to prevent lung
cancer in those smokers who are motivated
to stop yet have failed in smoking cessation
Table 1. Smoking and lung cancer: causative agents.a
programs. Considering the immense death
toll from lung cancer, chemoprevention
would make a significant impact even ifit
were successful in a relatively small
percentage ofsmokers.
Our approach to chemoprevention of
lung cancer is based on an understanding
of the carcinogens in tobacco smoke.
Tobacco smoke is a complex mixture of
compounds and contains at least 40 known
carcinogens. Carcinogens identified in cig-
arette smoke include polynuclear aromatic
hydrocarbons (PAHs), aza-arenes, which
are PAHs containing a nitrogen in the ring
system; nitrosamines; aromatic amines;
aldehydes; miscellaneous organic com-
pounds such as benzene, acrylonitrile, vinyl
chloride, 2-nitropropane, and ethyl carba-
mate; and inorganic compounds such as
hydrazine and various metals (4). Among
these, the PAHs and nitrosamines have in
their families the strongest respiratory car-
cinogens, while certain aldehydes and met-
als are also known respiratory carcinogens.
In contrast, some ofthe other carcinogens
such as aromatic amines and benzene are
associated with other cancers, such as blad-
der cancer and leukemia. The role ofspe-
cific carcinogens of tobacco smoke in
human cancers can be assessed byconsider-
ing the amounts of the carcinogens in
tobacco products, their target tissues and
carcinogenic potency in laboratory ani-
mals, and biochemical evidence that
humans and laboratory animals respond in
similar ways. Likely causative agents for
lung cancer are summarized inTable 1.
PAHs, typified by benzo[a]pyrene
(B[a]P), are formed by the incomplete
combustion of tobacco during smoking.
They are well-recognized carcinogens that
induce tumors ofthe lung in laboratory
animals exposed by inhalation, instillation
in the trachea, or implantation in the lung
(5-7). Squamous cell carcinomas ofthe
Carcinogens Modifying agents
Strong evidence
PAHs(B[a]P, benzo[bj, and klfluoranthenes, 5-methylchrysene, Co-carcinogens (catechols)
dibenz[a,hJanthracene, indeno[1,2,3-cd]pyrene) Tumor promoters(phenols and others)
NNK Toxic aldehydes(acrolein)
Diet
Weakevidence
210po, Cr, Cd, Ni
Aldehydes, butadiene
Free radicals and oxidative damage
"Criteria: animal carcinogenicity, presence in cigarette smoke, biochemical studies-animal and human lung.
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lung are generally induced by carcinogenic
PAHs such as B[a]P. Considering the
amounts of these compounds in cigarette
smoke and their carcinogenic potency, one
can plausibly argue that they are important
in lung cancer induction (4). This argu-
ment is bolstered by biochemical studies
that have demonstrated that human lung
tissue can metabolize PAHs by pathways
that lead to covalent modification ofDNA
and by the detection ofthe relevant DNA
adducts in lung tissue ofsmokers.
4-(Methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK), a nitrosamine formed
from the major tobacco constituent nico-
tine during tobacco processing and smok-
ing, is a powerful and organ-selective lung
carcinogen in laboratory animals (8). NNK
is one of a family of nicotine-derived
nitrosamines that are collectively called
tobacco-specific nitrosamines. Adeno-
carcinoma ofthe lung is the main type of
lung cancer induced by NNK. The total
amount ofNNK required to produce lung
cancer in rats is similar to the total amount
ofthis compound to which a smokerwould
be exposed in a lifetime ofsmoking (9,10).
These data support the role ofNNK in the
induction oflung cancer, particularly ade-
nocarcinoma. Moreover, human lung tissue
metabolically activates NNK, although not
as efficiently as rodent lung tissue (11).
DNA adducts specific to NNK and the
related nitrosamine N'-nitrosonornicotine
(NNN) have been detected in smokers'
lungs, and metabolites ofNNK are present
in smokers' urine (10,12).
Table 1 lists some other tobacco-smoke
constituents that could be involved in lung
cancer induction; the evidence suggesting a
role for these compounds is weaker than
that discussed above for PAHs and NNK.
Polonium-210 is present in cigarette main-
stream smoke and is a strong pulmonary
carcinogen, inducing tumors of the lung
upon inhalation in rats or on intratracheal
instillation in Syrian golden hamsters (4).
The significance of polonium-210 in
tobacco-induced lung cancer has been ques-
tioned based on comparisons ofdoses expe-
rienced by smokers versus miners. It has
been estimated that about 1% ofthe lung
cancer risk associated with cigarette smoking
could be ascribed to polonium-210.
Chromium, cadmium, and nickel are
all present in cigarette smoke (4). Calcium
chromate is carcinogenic in rats, inducing
lung tumors after instillation. Cadmium
chloride aerosols produce adenocarcinoma
and squamous cell carcinoma in rats.
Nickel subsulfide yields lung cancer in rats
upon inhalation. Because levels of expo-
sure to chromium, cadmium, and nickel
compounds in cigarette smoke may be
comparable to those ofsome PAHs, these
metal ions may play some role in lung
cancer induction.
Inhalation studies offormaldehyde and
acetaldehyde have demonstrated that they
are respir.atory carcinogens in the rat,
inducing mainly nasal cavity tumors (4).
There may be a direct effect ofthese com-
pounds on the lung upon inhalation in
tobacco smoke. Although they are weak
respiratory carcinogens, the levels of
formaldehyde and acetaldehyde in cigarette
smoke are at least 1000 times greater than
those ofPAHs and nitrosamines.
Cigarette smoke contains some stable
free radicals and is known to induce oxida-
tive damage (4,13). Products that result
from oxidative damage to both lipids and
DNA have been detected in smokers and
their levels are higher than in nonsmokers
(14,15). Although the direct role ofsuch
products in carcinogenesis is unclear,
8-oxoguanine, a DNA adduct detected at
elevated levels in smokers, has miscoding
properties associated with the cancer
induction process.
Collectively, the available evidence
favors PAHs and NNK as important com-
pounds responsible for lung cancer induc-
tion in smokers. Their role in lung cancer
is consistent with results of analyses of
mutations in the p53 and ras genes from
human lung tumors. These analyses have
demonstrated the presence ofa large num-
ber of G -* T transversions and G -4A
transitions in these genes, which is consis-
tent with mutational spectra expected from
PAHs and NNK (16-20).
With each cigarette, the smoker is
exposed to PAHs and NNK. As illustrated
in Figure 1, these carcinogens undergo
metabolic activation to DNA adducts. If
these adducts persist unrepaired during
DNA replication, miscoding can occur,
leading to permanent mutations in critical
genes such as p53 and ras, which are likely
to be important in the lung cancer induc-
tion process. Blocking any one of these
steps would decrease the probability of
lung cancer development. Our strategy has
been to block the metabolic activation step.
This approach will be discussed in this
report, using phenethyl isothiocyanate
(PEITC), a chemopreventive agent against
NNK-induced lung tumorigenesis, as one
example, and benzyl isothiocyanate
(BITC), an inhibitor of B[a]P-induced
lung tumorigenesis, as another. Other
known inhibitors of NNK- and B[a]P-
induced lung tumorigenesis will also be
reviewed. We emphasize that the ap-
proach discussed here is only one example
of strategies that can be employed for
chemoprevention oflung cancer.
Inhibition of NNK-induced
Lung Tumorigenesis
by PEITC
A naturally occurring isothiocyanate,
PEITC (PhCH2CH2N=C=S), is found as
its glucosinolate conjugate gluconasturtiin
in several vegetables including watercress.
PEITC is released from watercress upon
chewing by the action of myrosinase, a
thioglucosidase present in the plant
(21,22). Consumption ofapproximately 50
g of watercress releases 10 to 15 mg of
PEITC (22). When PEITC was added to
NIH-07, an open formula rodent diet, at a
concentration of498 ppm (3 pmol/g diet)
before and during treatment ofmale F344
rats with NNK, it caused a significant and
selective 50% reduction in the incidence of
adenocarcinoma ofthe lung (23) (Table 2).
There were no toxic effects of PEITC at
this dose. A single dose of 5 pmol of
PEITC administered to A/J mice 2 hr prior
to treatment with 10 pmol of NNK
resulted in a significant 62% reduction in
lung tumor multiplicity (24). Other studies
using multiple doses ofPEITC have shown
similar results in A/J mice (25,26). Thus
PEITC has been firmly established as an
effective inhibitor of lung tumorigenesis
induced byNNK in both rats and mice.
An overview of the major metabolic
activation and detoxification pathways of
NNK is illustrated in Figure 2 (27). In
laboratory animals and humans, NNK is
rapidly converted to 4-(methylnitros-
amino)-l-(3-pyridyl)-1-butanol (NNAL)
NNK
Metabolic DNA l) Persistence
G->T and G-*A
Lun Meabli DA 1)Pritne mutations in .- Lun
ivation adducts 2) Miscoding K-ras, p53, and cancer
other genes
PAHs
Figure 1. Relationship oftobacco-smoke carcinogen exposure, metabolic activation, DNA adductformation, muta-
tions, and lung cancer.
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Table 2. Incidence of lung, liver, and nasal cavitytumors aftertreatment with NNK, NNK+PEITC, and PEITC.a
Rats with tumors, no.
Lung Liver Nasal cavity
Treatment Rats, no. Adenoma Carcinoma Total (%) Adenoma Hepatocellular carcinoma Total (%) Benignb Malignantc Total (%)
NNK 40 8 24 32 (80) 12 3 15(38) 8 3 11(28)
NNK+PEITC 40 5 12d 17 (43)e 9 5 14(35) 6 1 7 (18)
PEITC 20 0 0 0 (0) 4 2 6(30) 0 1 1(5)
Control 20 1 0 1 (5) 3 1 4(20) 0 1 1 (5)
aData from Morse et al. (23). bSquamous cell papillomas, transitional-cell papillomas, polyps. cSquamous cell carcinoma. dOne squamous cell carcinoma, 11 adenocarcino-
mas. ep<0.05 compared to NNK group.
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Figure 2. Metabolism of NNK: an overview.
by carbonyl reductase enzymes. Also a
potent pulmonary carcinogen, NNAL is
partially converted to its diastereomeric glu-
curonides, [4-(methylnitrosamino)-1-(3-
pyridyl)but-1-yl]-3-O-D-glucosiduronic
acid (NNAL-gluc). These glucuronides are
likely detoxification'products of NNK.
Pyridine N-oxidation ofNNK and NNAL
gives the corresponding N-oxides, which
are detoxification products. Metabolic acti-
vation of NNK proceeds by ax-hydroxyla-
tion ofthe methylene and methyl carbons
producing unstable intermediates 1 and 2.
These spontaneously decompose with for-
mation ofaldehydes and the electrophilic
diazohydroxides 4 and 5. Diazohydroxide 4
methylates DNA of NNK target tissues,
producing permanent mutations, mainly of
the G - A type. Diazohydroxide 5 alkylates
DNA producing both G ->A and G-* T
mutations. It also reacts with hemoglobin to
form ester adducts. Hydrolysis of DNA or
hemoglobin obtained from animals treated
with NNK or from smokers produces
4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)
(6), which is a biomarker ofthe metabolic
activation of NNK (28). Smokers' urine
contains quantifiable amounts of NNAL
andNNAL-gluc as biomarkers.
The mechanism ofNNK carcinogenesis
inhibition by PEITC has been examined.
Initial studies demonstrated that PEITC
inhibited the metabolic activation ofNNK
to electrophiles, which methylate and
pyridyloxobutylate pulmonary DNA in
rats (23). Subsequently, detailed investiga-
tions of the effects of PEITC on NNK
metabolism in mouse and rat liver and
lung, as well as studies of other enzyme
activities, have clearly demonstrated that
the inhibitory effect of PEITC on NNK
carcinogenesis is due mainly to inhibition
ofNNK metabolic activation to methylat-
ing and pyridyloxobutylating electrophiles
(29,30). In rats treated with PEITC by gav-
age or by addition to the diet, a persistent
inhibition ofmetabolic activation ofNNK
is observed in lung microsomes, which
results from inhibition ofcytochrome P450
enzymes. In contrast, a persistent inhibition
in liver microsomes is not observed.
Experiments in vitro have shown that
PEITC is a competitive inhibitor ofNNK
metabolic activation in rat lung micro-
somes, with the concentration that inhibits
50% ranging from 150 to 210 nM, and in
explants ofratlung (30,31).
The effects ofPEITC on NNK metabo-
lism have also been examined in vivo. In
these experiments, the goal was to deter-
mine whether the observed inhibition of
tumorigenesis was due to specific inhibition
of metabolic activation of NNK, or
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Table 3. Effect of PEITC on excretion of NNAL and NNAL-gluc in rats treated with NNK.a
Metabolites in urine, nmol/24 hr
Group NNAL NNAL-gluc Total Fold increase in total
68-week datab
NNK 4.1 ±1.0 9.4±3.8 13.5±4.8 -
NNK+PEITC 11.6±2.5 44.6± 15.8 56.1 ± 17.9 4.2*
79-week datac
NNK 3.1 8.8 11.9 -
NNK+ PEITC 14.3 ± 5.7 59.6 ± 36.8 73.9 ± 42.4 6.2*
'NNK in drinking water (2 ppm): PEITC in diet (3 pmol/g) for 68 or 79 weeks. bMetabolites: mean±SD, n=3.
c\Mean oftwo rats (NNK group); mean ±SD, n=3 (PEITC group). *p<1 x10.4
whether treatment with PEITC might have
caused a change in distribution of NNK
resulting in diminished amounts ofthe car-
cinogen reaching extrahepatic tissues. In
experiments carried out using a protocol
essentially identical to that employed in the
carcinogenicity studydescribed above, itwas
shown that the levels ofNNK and its pri-
mary metabolite NNAL were not markedly
different in tissues of PEITC treated and
control rats. However, the data dearly indi-
cated a decrease in the levels ofNNK meta-
bolic activation in the PEITC treated rats in
almost all tissues examined (32).
The effects ofchronic PEITC treatment
on hemoglobin adducts and urinary meta-
bolites of NNK have been examined in
rats. Results of the urinary metabolite
analyses are summarized in Table 3.
Chronic PEITC treatment caused sig-
nificant 4- to 6-fold increases in the levels
of NNAL and NNAL-gluc in urine; this
most likely results from a decrease in meta-
bolic activation ofNNK since hemoglobin
adducts ofNNK also decreased (data not
shown). The ratio of NNAL-gluc to
NNAL, a potential biomarker of NNK
detoxification, increased upon PEITC
treatment. Collectively, the results ofthese
studies clearly show that PEITC exerts a
specific inhibitory effect on the metabolic
activation of NNK without causing any
apparent toxic effects in rats.
Inhibition of B[a]P-induced
Lung Tumorigenesis
by Benzyl Isothiocyanate
Whereas PEITC is an effective inhibitor of
lung carcinogenesis by NNK, studies to
date have not demonstrated efficacy with
respect to B[a]P. In one study in A/J mice,
PEITC was administered by gavage prior
to ip injection of B[a]P. No inhibition of
B[a]P-induced lung tumorigenesis was
observed over a range of PEITC doses
(33). In a second study, a single dose of
6.7-jmol PEITC was given by gavage to
A/J mice 15 min prior to gavage of
7.9-pmol of B[a]P. No inhibition oflung
tumorigenesis was observed, although
PEITC did inhibit forestomach tumor
induction by B[a]P. In contrast, a
7.9-pmol dose ofBITC given by the same
protocol did result in a statistically signifi-
cant 50% reduction ofB[a]P-induced lung
tumor multiplicity in the A/J mouse model
(Table 4) (34). These results are in agree-
mentwith previously reported data on inhi-
bition ofB[a]P-induced lung tumorigenesis
by BITC (35). The contrasting effects of
PEITC and BITC on lung tumorigenesis
by B[a]P in A/J mice are consistent with
mechanistic studies, which have shown
that BITC but not PEITC significantly
inhibited ethoxyresorufin O-dealkylase
activity in A/J mouse lung microsomes,
which is indicative of inhibition of
P4501A. P4501A may be involved in the
metabolic activation of B[a]P (30). In
ongoing studies, we are examining the
effects of BITC and PEITC on the meta-
bolic activation and DNA binding of
B[a]P inA/J mouselung and liver (36).
Inhibitors of Lung
Tumorigenesis Induced
by NNK or B[a]P
The studies described above indicate that
two isothiocyanates, PEITC and BITC,
inhibit metabolic activation and lung
tumorigenesis of NNK and B[a]P,
respectively. The data for PEITC are now
particularly strong and recent studies
Table 4. Effects of BITC and PEITC on B[a]P-induced
lung and forestomach tumorigenesis in A/J mice.a
Mice with tumors, % Tumors per mouse
Group Lung Forestomach Lung Forestomach
B[a]P only 95 95 4.8 4.8
BITC/B[a]P 80 95 2.6* 4.9
PEITC/B[a]P 90 90 4.0 2.5*
'Data from lin et al. (34). Female mice given 6.7-pmol
isothiocyanate ig 15 min priorto 7.9-pmol B[a]P 3times
at 2-week intervals and sacrificed 26 weeks after first
dose. *p<0.001.
indicate that PEITC will also inhibit the
metabolic activation of NNK in smokers
(below). Although few compounds other
than PEITC have been investigated as
extensively as chemopreventive agents
against lung cancer induced by NNK or
B[a]P, there exists nevertheless a rich
selection of compounds that have shown
inhibitory activity against NNK- or
B[a]P-induced lung tumorigenesis in
rodents. Compounds tested as inhibitors of
NNK-induced lung tumorigenesis are
summarized in Table 5. Although this
table includes only defined compounds,
certain mixtures such as green tea, black
tea, snuffextract, orange oil, and NIH-07
diet also inhibit NNK-induced tumorigen-
esis; however, the responsible compounds
have not been identified (43,49,52-54).
More than 25 inhibitors ofNNK-induced
lung tumorigenesis are known (Table 5).
Isothiocyanates appear to be the strongest
inhibitors according to presently available
data. Other inhibitors include natural
products such as sinigrin, indole-3-
carbinol, D-limonene, diallyl sulfide,
epigallocatechin-3-gallate, and ellagic acid;
antioxidants such as butylated hydrox-
yanisole; and drugs such as sulindac,
ibuprofen, and piroxicam. Other com-
pounds, such as the ipomeanol analogue
7-hydroxy-1-phenyl-1-octanone, the P450
suicide inhibitor 4-phenyl-1-butyne, and
the organoselenium compound 1,4-
phenylenebis(methylene)selenocyanate,
have been developed based on mechanistic
considerations and by analogy to other
chemopreventive agents. All compounds
tested to date have shown activity when
administered before or concurrently with
NNK. There are no reported suppressors
ofNNK-induced lung tumorigenesis, e.g.,
agents that are effective when administered
only after NNK treatment.
Compounds tested as inhibitors of
B[a]P-induced lung tumorigenesis are
listed in Table 6. At least 20 inhibitors
have been identified. Some of the
inhibitory compounds are the same as
those that inhibit NNK-induced lung
tumorigenesis; these include butylated
hydroxyanisole, ellagic acid, and diallyl sul-
fide. As in the case ofNNK, the inhibitors
include natural products, drugs, and
antioxidants. Only three compounds-
myo-inositol, dexamethasone, and buty-
lated hydroxyanisole-have been shown to
inhibit B[a]P-induced lung tumorigenesis
when administered after B[a]P.
Neither 5-carotene nor vitamin A has
shown reproducible inhibitory effects on
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Table 5. Inhibition of NNK-induced lung tumorigenesis.a
Compound Strain and species Protocol type Result Reference
Isothiocyanates(R-N=C=S)R=
Benzyl A/~~~~~J mouse Pre/post No effect (37,38)
N/J mouse Post No effect (38)
3-Phenylpropyl N/J mouse Pre Inhibition (25,26)
5-Ph I A/~~~~~J mouse Pre Inhibition (40)
B-Phenyloctyl A/~J mouse Pre-o Inhibition (440t4)
Epiga iphocatehyn 3Aalat J mouse P-cn Inhibition (49)
Alloyanl NJmouse Pre No effect .(5 ..0)
2-Hexyl ~ ~ ~ ~ ~ NJmouse Pre-o Ihibition (47)
1 NJ mousePre-conInhibition(51)~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~. .......... .. ... ... U~~~~~~~~~~~~~~~~~~~~~.......I-. 1-11 "E
4-0xen4l-3-penyriyIbuyNAJ mouse Pre' INhibifetio (392)
poundsaredconsidered.n Ihiiton .(4,5
lung cancer induction in rodents treated
with either NNK or B[a]P. In view of this
finding, it is perhaps not surprising that
,-carotene was ineffective in a trial as a
chemopreventive agent against lung cancer
in smokers (81).
Effects of Watercress
Consumption on NNK
Metabolism in Smokers
The studies described above demonstrate
that PEITC inhibits NNK-induced lung
tumorigenesis in rats and mice by in-
hibiting its metabolic activation. We
wanted to determine whether similar
effects would occur in smokers. The
source of PEITC used in this study was
watercress (Nasturtium officinale), which
contains substantial amounts ofgluconas-
turtiin, the glucosinolate precursor of
PEITC (22).
Eleven smokers maintained constant
smoking habits and avoided cruciferous veg-
etables and other sources ofisothiocyanates
throughout the study (82). They donated
24-hr urine samples on 3 consecutive days
(baseline period). After 1 to 3 days, they
began the watercress consumption period, 3
days during which they consumed 2 oz
(56.8 g) of watercress at each meal and
donated 24-hr urine samples on each day.
One and two weeks later theyagain donated
24-hr urine samples on 2 to 3 consecutive
days (follow-up periods). The samples were
analyzed for two metabolites of NNK;
NNAL and NNAL-gluc, as well as N-acetyl-
S-(N-phenethylthiocarbamoyl)-L-cysteine
(PEITC-NAC), a metabolite of PEITC.
Minimum exposure to PEITC during the
watercress consumption period averaged 19
to 38 mg per day. Seven ofthe eleven sub-
jects had increased levels ofurinary NNAL
plus NNAL-gluc on days 2 and 3 of the
watercress consumption period, compared
to the baseline period. Overall, the increase
in urinary NNAL plus NNAL-gluc in this
period was significant [mean ± SD,
0.924± 1.12 nmol/24 hr (33.5%),p<0.0l].
Urinary levels ofNNAL plus NNAL-gluc
returned to near baseline levels in the fol-
low-up periods. The percent increase in uri-
nary NNAL plus NNAL-gluc during days 2
and 3 ofthe watercress consumption period
correlated with PEITC intake during this
period as measured by total urinary
PEITC-NAC (r= 0.62, p= 0.04). The
results ofthis study support our hypothesis
that PEITC inhibits the oxidative metabo-
lism ofNNK in humans, as seen in rodents,
and support further development ofPEITC
and other compounds as chemopreventive
agents against lung cancer.
Summary
The research described in this paper
conclusively demonstrates that a large
number ofcompounds can inhibit the lung
tumorigenicity of the important tobacco-
smoke pulmonary carcinogens NNK and
B[a]P in rodent models. Among these,
isothiocyanates have been investigated
extensively with respect to efficacy and
mechanisms ofinhibition. One ofthe most
thoroughly studied isothiocyanates,
PEITC, inhibits lung tumor induction by
NNK in rodents, and apparently in smok-
ers, by inhibiting the metabolic activation
ofNNK. Considering the large number of
chemopreventive agents that are effective
against lung tumorigenesis by either NNK
or B[a]P, it seems likely that appropriately
designed mixtures ofagents should be effec-
tive against both NNK and B[a]P. An A/J
mouse lung tumorigenesis model for testing
the efficacy of chemopreventive agents
against NNK and B[a]P is available (83).
Development of chemopreventive agents
against other carcinogens in tobacco smoke
is also important, not only with respect to
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Table 6. Inhibition of B[ajP induced lung tumorigenesisa
Compound Strain and species Protocol type Result Reference
Vitamin Apalmitate Syrian hamster PostIniton(5
Sodium seleniteSynan hamster Pre-con ~~~noeffect (9
Phenmethlenisohoynt NJiamouster Pre-con No effect (33)
Bhenetyl isothiocyanate NJmouse Pe IhiitonNoefc (3435)
Butzylaistedhydoxyanisoe NHeJmouse Pre pecn Inhibition (64465)
Sodiumcyanate ~~~~~~~~~~~~ ~ ~~~~~~ICR/Ha mouse Pre-con Inhibition (68)
-~
A IIzi4M 4'
Chiorogetnipnacid hl -her A/HJ mouse Pre cnInhibition (69)
Newbrn a (iR) re o efect(70
M ~~ ~ ~ ~ ~ I t11SJnt* si mi. M ~ ~ ~ He mose Pr cn-oefec (1
A 4 .-.. ~ ,,~
Butyatedhydrxyansole A/HJ.mouse Pre,pecn Ihbto 666 .,~~~~~~~~~~~~~ ......~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.. ....4.........
Dprtopylsulfid N/HJ mouse Pre-o No effect
;!No (73)
Mt -h ..-=. .1
Uaodium o-gacuate NHJmuePr6o8nibto 7)
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lung cancer, but also for inhibition ofother
cancers caused by smoking.
Most ofthe inhibitors discussed in this
paper must be present at the time of car-
cinogen administration to be effective,
since in many cases they are inhibitors of
metabolic activation or enhancers of car-
cinogen detoxification. This raises ques-
tions about their potential efficacy,
depending on how tobacco carcinogenesis
is viewed. Two models of tobacco
carcinogenesis are outlined in Figure 3.
In the classical sequential model, initia-
tion by compounds such as NNK or
B[a]P is followed by promotion and pro-
gression. Tobacco smoke contains tumor
promoters, and the partial reversibility of
lung cancer risk associated with smoking
cessation is consistent with the reversibil-
ity of promotion. However, this model
A
Initiation -* Promotion -* Progression
(PAH/NNK) (weak acids) (diet, alcohol,
other cofactors)
B
DNA-damaging
carcinogens
(PAH/NNK)
Other DNA-
damaging agents
(oxygen radicals,
nitrogen oxides)
Multiple genetic
changes (p53, ras)
Toxic and
cocarcinogenic
agents
catechols) Enhancing effects
Modifying factors
(diet/others)
Figure 3. Two models of tobacco-induced lung cancer.
(A) In the classical sequential model, exposure to a
DNA-damaging initiating compound is followed by
exposure to compounds that cause promotion and pro-
gression. (B) In the chronic exposure model, continual
simultaneous exposure to all cigarette-smoke com-
pounds leads to multiple genetic changes and other
effects associated with carcinogenesis.
may be somewhat unrealistic. Smokers are
simultaneously exposed to carcinogens,
promoters, cocarcinogens, and toxic com-
pounds with every cigarette. Therefore,
the chronic exposure model may be more
realistic and is consistent with the concept
that multiple genetic changes are involved
in the carcinogenic process. These changes
will be decreased by favorable alteration
of several steps involved in carcinogen-
related gene changes (Figure 1).
Protocols should be developed to iden-
tify agents that would be effective against
all known steps in the lung-cancer induc-
tion process; typical animal data are
summarized in Tables 5 and 6, and by
Moon et al. (84).
There is a clear need for identification
of suppressing agents (compounds active
after carcinogen exposure) in future
studies, in part because there are a large
number of ex-smokers who would benefit
from chemoprevention. Such compounds
would inhibit nongenotoxic aspects oflung
carcinogenesis. Only a few suppressing
agents are known at present that are active
against lung tumors induced by tobacco
smoke carcinogens. The further develop-
ment of such agents should be a major
research priority.
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NOTE ADDED IN PROOF: Further
studies by Wattenberg and Estensen
demonstrated the efficacy of myo-inositol
and dexamethasone as suppressors of
pulmonary tumorigenesis (85). The
inhibitory effect ofPEITC against rat lung
tumorigenesis induced by NNK was
demonstrated in two further studies:
Chung et al. (86) and Hecht et al. (87).
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